View of 1075 – Translating phase III trials into real-world practice: evaluation of pathologic complete response in HER2-positive breast cancer and the potential impact of antibody–drug conjugates in the neoadjuvant setting

Return to Article Details 1075 – Translating phase III trials into real-world practice: evaluation of pathologic complete response in HER2-positive breast cancer and the potential impact of antibody–drug conjugates in the neoadjuvant setting Download Download PDF